Mergers & Acquisitions ·
ANI Pharmaceuticals proposes $560M cash offer for Swedish rare disease firm Egetis Therapeutics
ANIPAni Pharmaceuticals Inc
ANI Pharmaceuticals announced a recommended public cash offer to acquire all outstanding shares, convertible notes, and warrants of Egetis Therapeutics AB. The bid values the transaction at approximately SEK 5.6 billion ($560 million), offering SEK 11.25 per share, plus specific cash consideration for the Convertible and Warrants. The offer carries a 27% premium to the 60-day volume-weighted average price and is backed by irrevocable undertakings from shareholders holding approximately 42.2% of Egetis. Financing includes a new $676 million senior bridge facility with JPMorgan Chase. ANI, a diversified biopharmaceutical company focused on rare diseases, generics, and brands, aims to accelerate the U.S. commercialization of Egetis' lead asset, EMCITATE.